

Bempedoic Acid Mechanism of Action
ACSVL1
BA
CoA conjugate of BA
Citrate
ATP-citrate lyase (ACL)
Acetyl-CoA
HMG-CoA
Statin
HMG-CoA reductase
Mevalonic acid
Squalene
Cholesterol
LDL-R
LDL-C Clearance
Plasma LDL-C

FIG. 1



Bempedoic Acid
Placebo
Change in HbA1C level in patients
0.15%
-0.01%
0.04%
-0.15%
Week 52
Week 12
0.2
0.15
0.1
0.05
0
-0.05
-0.1
-0.15
-0.2
Change in HbA1c (%)

FIG. 2



Change in fasting glucose level in patients
Bempedoic Acid
Placebo
Change in Fasting Glucose (mg/dl)
20
18
16
14
12
10
8
6
4
2
0
Baseline
Week 4
Week 8
Week 12
Week 24
Week 36
Week 52

FIG. 3



Bempedoic Acid
Placebo
Change in HbA1C level in patients
Change in HbA1c (%)
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
-0.05
N=24
0.34%
N=57
0.05%
N=25
0.16%
N=61
-0.03%
Week 12
Week 24

FIG. 4



Bempedoic Acid
Placebo
Change in fasting glucose level in patients
Change in Fasting Glucose (mg/dl)
20
15
10
5
0
-5
Baseline
Week 4
Week 12
Week 24
N=63
N=61
N=61
N=57
N=26
N=25
N=23
N=24

FIG. 5



Bempedoic Acid
Placebo
Change in HbA1C level in patients
Change in HbA1c (%)
0.3
0.25
0.2
0.15
0.1
0.05
0
-0.05
N=35
0.28%
N=17
-0.03%
Week 12

FIG. 6



Bempedoic Acid
Placebo
Change in fasting glucose level in patients
Change in Fasting Glucose (mg/dl)
30
25
20
15
10
5
0
-5
-10
Baseline
Week 4
Week 8
Week 12
N=15
N=15
N=17
N35
N=17
N=35
N=35
N=35

FIG. 7



Bempedoic Acid
Placebo
Bempedoic Acid + Ezetimibe
Ezetimibe
Change in fasting glucose level in patients
Change in Fasting Glucose (mg/dl)
30
25
20
15
10
5
0
-5
-10
Baseline
Week 4
Week 8
Week 12
N=45
N=41
N=48
N=58
N=22
N=55
N=57
N=23
N=55
N=24
N=58
N=57

FIG. 8